On August 20, MEDBOT-B rose 6.24% in regular trading, trading at 24.9 HKD/share, with turnover of 18.602 million HKD.

On the news front, the company previously announced that its board of directors will convene on August 27 to review interim results for the six months ended June 30. Additionally, Da Hua Securities initiated coverage with a \"Buy\" rating and a target price of 29 HKD. The Health Care Equipment sector rallied broadly, with MICROPORT up 7.11%, LIFETECH SCI up 3.73%, and AK MEDICAL up 2.84%.

Earlier, the company issued a positive profit alert, forecasting first-half net profit of RMB 28 million to 40 million, compared to a net loss of RMB 115 million in the same period last year, marking its first-ever half-year profitability. Revenue is expected to surge approximately 200% to 230% year-over-year, driven by strong sales of the Toumai laparoscopic surgical robot, with overseas revenue growing over 450% and overall gross margin improving by more than 15 percentage points.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)